(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...